Diagnostic and Management Issues in Patients with Late-Onset Ornithine Transcarbamylase Deficiency

• Published in: Children (Basel) Vol. 10; no. 8; p. 1368
• Main Authors: Ibrahim, Majitha Seyed, Gold, Jessica I, Woodall, Alison, Yilmaz, Berna Seker, Gissen, Paul, Stepien, Karolina M
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-08-2023; MDPI
• Subjects: adults; Amino acids; Ammonia; Brain damage; Care and treatment; Chemotherapy; clinical manifestations; Enzymes; Gastrointestinal surgery; Genetic aspects; Health aspects; Laboratories; late-onset OTC deficiency; Liver diseases; Medical diagnosis; Medical screening; Metabolism; Metabolites; Migraine; Mortality; Mutation; Patients; Plasma; Proteins; Review; Urea; urea cycle disorders; Urine; United Kingdom
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children10081368

Ornithine transcarbamylase deficiency (OTCD) is the most common inherited disorder of the urea cycle and, in general, is transmitted as an X-linked recessive trait. Defects in the OTC gene cause an impairment in ureagenesis, resulting in hyperammonemia, which is a direct cause of brain damage and death. Patients with late-onset OTCD can develop symptoms from infancy to later childhood, adolescence or adulthood. Clinical manifestations of adults with OTCD vary in acuity. Clinical symptoms can be aggravated by metabolic stressors or the presence of a catabolic state, or due to increased demands upon the urea. A prompt diagnosis and relevant biochemical and genetic investigations allow the rapid introduction of the right treatment and prevent long-term complications and mortality. This narrative review outlines challenges in diagnosing and managing patients with late-onset OTCD.